FR-260010

FR-260010
[[File:|frameless|220px|alt=|Chemical structure of FR-260010]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

FR-260010 is a chemical compound that has been studied for its potential pharmacological effects. It is primarily of interest in the field of cardiovascular pharmacology due to its action as a potassium channel opener. This compound has been investigated for its ability to induce vasodilation and its potential therapeutic applications in treating conditions such as hypertension and angina pectoris.

Pharmacodynamics

FR-260010 functions by opening ATP-sensitive potassium channels (K_ATP channels) in vascular smooth muscle cells. This action leads to hyperpolarization of the cell membrane, which in turn causes relaxation of the smooth muscle and vasodilation. The opening of these channels reduces intracellular calcium levels, further contributing to muscle relaxation.

Pharmacokinetics

The pharmacokinetic profile of FR-260010 includes its absorption, distribution, metabolism, and excretion. Studies have shown that it is rapidly absorbed when administered orally, with a bioavailability that allows for effective plasma concentrations to be reached. The compound is metabolized primarily in the liver, and its metabolites are excreted via the renal route.

Clinical Applications

While FR-260010 has shown promise in preclinical studies, its clinical applications are still under investigation. The primary focus has been on its use as an antihypertensive agent and in the management of ischemic heart conditions. However, further clinical trials are necessary to fully establish its efficacy and safety profile.

Side Effects

Potential side effects of FR-260010, as with other potassium channel openers, may include hypotension, dizziness, and headache. These effects are generally related to its vasodilatory action.

Research and Development

Research on FR-260010 is ongoing, with studies focusing on its mechanism of action, therapeutic potential, and safety. The compound is part of a broader class of drugs being explored for their cardiovascular benefits.

Also see

• Potassium channel openers
• Vasodilators
• Hypertension treatment
• Cardiovascular pharmacology

References

This article is a stub related to pharmacology. You can help WikiMD by expanding it!